These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308 [TBL] [Abstract][Full Text] [Related]
3. Posttransplant lymphoproliferative disorder after liver and kidney transplant. Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813 [TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306 [TBL] [Abstract][Full Text] [Related]
5. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085 [TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541 [TBL] [Abstract][Full Text] [Related]
10. Two-year experience with FK 506 in pediatric patients. Tzakis AG; Reyes J; Todo S; Nour B; Shapiro R; Jordan M; McCauley J; Armitage J; Fung JJ; Starzl TE Transplant Proc; 1993 Feb; 25(1 Pt 1):619-21. PubMed ID: 7679822 [No Abstract] [Full Text] [Related]
11. Neoral is superior to FK 506 in liver transplantation. Levy GA Transplant Proc; 1998 Aug; 30(5):1812-5. PubMed ID: 9723293 [No Abstract] [Full Text] [Related]
12. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763 [TBL] [Abstract][Full Text] [Related]
13. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647 [TBL] [Abstract][Full Text] [Related]
14. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Kiuchi T; Tanaka K; Inomata Y; Uemoto S; Satomura K; Egawa H; Uyama S; Sano K; Okajima H; Yamaoka Y Transplant Proc; 1996 Dec; 28(6):3171-2. PubMed ID: 8962229 [No Abstract] [Full Text] [Related]
15. Thirteen years' experience in pediatric liver transplantation: differences between tacrolimus and cyclosporine. Zajicek A; Esquivel C; Millan M; Cox K; Berquist R; Berquist W Transplant Proc; 2002 Aug; 34(5):1976-8. PubMed ID: 12176653 [No Abstract] [Full Text] [Related]
16. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581 [TBL] [Abstract][Full Text] [Related]